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Background: The next generation magnetic nanoparticles (MNPs) with theranostic   applications 
have attracted significant attention and will greatly improve nanomedicine in cancer therapeutics. 
Such novel MNP formulations must have ultra-low particle size, high inherent magnetic 
properties, effective imaging, drug targeting, and drug delivery properties. To achieve these 
characteristic properties, a curcumin-loaded MNP (MNP-CUR) formulation was developed.
Methods: MNPs were prepared by chemical precipitation method and loaded with curcumin (CUR) 
using diffusion method. The physicochemical properties of MNP-CUR were characterized using 
dynamic light scattering, transmission electron microscopy, and spectroscopy. The internalization 
of MNP-CUR was achieved after 6 hours incubation with MDA-MB-231 breast cancer cells. 
The anticancer potential was evaluated by a tetrazolium-based dye and colony formation assays. 
Further, to prove MNP-CUR results in superior therapeutic effects over CUR, the mitochondrial 
membrane potential integrity and reactive oxygen species generation were determined. Magnetic 
resonance imaging capability and magnetic targeting property were also evaluated.
Results: MNP-CUR exhibited individual particle grain size of ∼9 nm and hydrodynamic average 
aggregative particle size of ∼123 nm. Internalized MNP-CUR showed a preferential uptake in 
MDA-MB-231 cells in a concentration-dependent manner and demonstrated accumulation 
throughout the cell, which indicates that particles are not attached on the cell surface but 
internalized through endocytosis. MNP-CUR displayed strong anticancer properties compared 
to free CUR. MNP-CUR also amplified loss of potential integrity and generation of reactive 
oxygen species upon treatment compared to free CUR. Furthermore, MNP-CUR exhibited 
superior magnetic resonance imaging characteristics and significantly increased the targeting 
capability of CUR.
Conclusion: MNP-CUR exhibits potent anticancer activity along with imaging and   magnetic 
targeting capabilities. This approach can be extended to preclinical and clinical use and 
may have importance in cancer treatment and cancer imaging in the future. Further, if these 
nanoparticles can functionalize with antibody/ligands, they will serve as novel platforms for 
multiple biomedical applications.
Keywords: magnetic nanoparticles, drug delivery systems, magnetic resonance imaging, 
nanomedicine, cancer therapeutics, biomedical applications
Introduction
Breast cancer is a commonly diagnosed cancer among women in the United States. 
It is estimated that 230,480 women were diagnosed with, and 39,520 women died 
from, breast cancer in 2011 in the United States.1 Basal-like breast cancer accounts for 
15% of all breast cancers and has a poor prognosis. The majority of these cancers are 
referred to as triple-negative breast cancers because they do not over express estrogen 
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receptor, progesterone receptor, or human epidermal growth 
factor receptor 2.2,3 Chemotherapy is an effective option to 
treat such cancers; however, chemotherapy is always associ-
ated with several sets of side effects.4–7 To overcome/avoid 
issues with side effects, natural compounds which are used 
as daily food ingredients may be an alternative option.
Among many food ingredients, curcumin (CUR), a natural 
diphenol extracted from the ground rhizomes of Curcuma 
longa, possesses a number of potentially beneficial biological 
characteristics including anticancer and chemoprevention 
properties.8 MDA-MB-231 cancer cells are one example of 
a triple-negative breast cancer and are highly metastatic in 
nature. CUR can effectively upregulate p53, p21, and p27 
and downregulate cyclin E; thus, cell cycle arrest occurs at 
the G1 phase in these cancer cells.9 CUR also decreases cell 
viability and anchorage independency of MDA-MB-231 
cancer cells by induction of apoptosis and inhibits constitutive 
STAT3 signaling.10 Another study confirmed that CUR 
enhances cellular localization and phosphorylation, induces 
DNA damage and modulates BRCA1 in triple-negative breast 
cancer cells.11 Additionally, synergistic antiproliferation 
effects of CUR were observed when used in conjunction with 
chemotherapeutic drugs or radiation.12–14 A recent review 
article suggests the specific role of CUR towards cancer 
cells versus normal cells.15 Specifically, CUR does not show 
significant toxicity towards normal human cells. However, 
successful implementation of CUR into the clinical arena 
must overcome issues related to its solubility, degradation in 
physiological medium, and rapid metabolism.16 This can be 
achieved through advanced drug delivery systems.16,17 Recent 
studies demonstrate CUR entrapped or encapsulated in 
nanocarriers, such as polymer nanoparticles, nanoassemblies, 
and self-assemblies, can enhance internalization/localization 
and thus induce cytotoxicity and apoptosis in cancer 
cells.18–22 Similarly, CUR nanoformulations (nanomedicine 
of CUR) based on conjugate, emulsion, lipid, polymer, 
and gel nanoparticles have been proposed for improving 
therapeutic benefits and sensitization for chemotherapy and 
radiation.16,17,23
Magnetic nanoparticles (MNPs; mostly iron oxide nano-
particles) are widely used in various medical applications. 
MNPs have been utilized as nanocarriers for drugs, contrast 
imaging agents in magnetic resonance imaging (MRI), in 
local hyperthermia, and magnetic targeting.24,25 However, 
high aggregation of MNPs is a common problem. High 
surface-to-volume ratios and van der Waals forces trigger 
opsonization and therefore, present a major obstacle for 
biomedical applications. This phenomenon can be altered 
by engineering the surface of the MNPs through various 
stabilizer coatings including surfactants and synthetic and 
natural polymers.25 Additionally, some reports suggest that 
some polymer coatings on the surface of MNPs can change 
the contrast imaging properties appropriate for both T1 and 
T2 imaging.26
Advances in cancer nanotechnology increase the use 
of novel therapeutic strategies such as nanotheranostics, 
which utilize individualized diagnostic therapy.27 The 
interest here was to develop a magnetic nanoformulation 
without compromising its basic imaging and drug delivery 
characteristics. To date, a wide variety of modalities have 
been formulated with MNP platforms that contribute not 
only to drug delivery but also exhibit photothermal therapy, 
thermosensitive chemotherapy, and visible/luminescence/near 
infrared/multimodal imaging.26,28,29 Such nanoformulation 
applicability relies on the design and stabilizer coatings 
which provide biocompatibility, high therapeutic drug 
loading capability, stability in biological milieu, and proper 
intracellular uptake by cancer cells. Crosslinked dextran-
coated MNPs are recognized as an example of a nanoplatform 
with multiple functions.30 The engineered structure of this 
formulation maintains a targeting feature and diagnostic 
imaging properties for MRI, optical, and positron emission 
tomography modalities. Many important formulations have 
been developed and the iron oxide nanocore stabilized with 
a double layer coating has frequently proved to be feasible 
for theranostic purposes.31,32 However, these formulations 
usually exhibit a higher hydrodynamic diameter in aqueous 
medium ($250 nm) which limits their use as efficient 
therapeutic carriers for medicinal applications. Therefore, 
herein, a rationally designed MNP with improved features 
was developed. This formulation was composed of an iron 
oxide core coated with β-cyclodextrin (CD) and pluronic F68 
polymer (polyethylene oxide-co-polypropylene oxide-co-
polyethylene oxide) that allows loading of anticancer drugs 
(in this study, CUR). This formulation was examined for its 
anticancer properties, magnetic targeting, and MRI in triple-
negative breast cancer (MDA-MB-231) cells.
Materials and methods
Chemicals and cell culture
All chemicals and reagents were purchased from Sigma-
Aldrich Corporation (St Louis, MO) unless otherwise 
specified. Difco® bacto-nutrient agar dehydrated was 
purchased from BD Diagnostics (Franklin Lakes, NJ). 
Milli-Q® purified water (Millipore Corporation, Billerica, 
MA) was used to make all aqueous solutions. MDA-MB-231 
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breast cancer cells were kindly gifted by Dr W Keith 
Miskimins (Cancer Biology Research Center, Sanford 
Research/University of South Dakota, Sioux Falls, SD). 
This cell line was maintained as monolayer culture in 
Dulbecco’s modified Eagle’s medium (high glucose; Thermo 
Scientific HyClone, Logan, UT) supplemented with 10% 
fetal bovine serum (Atlanta Biologicals Inc, Lawrenceville, 
GA) and Gibco® 1% penicillin-streptomycin (Invitrogen 
Life Technologies, Carlsbad, CA) at 37°C in a humidified 
atmosphere (5% carbon dioxide).
Preparation of MNP and MNP-CUR 
formulations
Iron oxide nanoparticles were prepared using a minor 
modification of a protocol reported by Yallapu et al.22 Briefly, 
100 mg of CD and 45 mL of water containing 810 mg of 
iron(3+) and 297 mg of iron(2+) ions (molar ratio 2:1) 
was placed in a 100 mL beaker. To this solution, 3 mL of 
ammonium hydroxide (28% ammonia in water) was slowly 
added at a stirring speed of 900 rpm. After 6 hours, 200 mg 
of pluronic polymer F68 (average molecular weight 8350) 
in 5 mL water was added to the nanoparticle suspension and 
stirred overnight. After five washes with water,33 the nano-
particles were resuspended in 25 mL water and centrifuged 
at 1000 rpm to remove larger aggregates. This formulation 
was designated as MNP.
To load CUR in the MNPs, 1 mg CUR in 200 µL acetone 
was added dropwise to 2.75 mL of an aqueous dispersion 
of MNPs (10 mg). The mixture was stirred overnight at 400 
rpm on a magnetic plate to facilitate the penetration of CUR 
molecules into the CD or CD-F68 polymer layers in the 
formulation. The drug-loaded nanoparticles were washed 
three times by resuspending them in water and separated with 
the help of magnets.33 These drug-loaded nanoparticles were 
dispersed in 2 mL sterile phosphate buffered saline (PBS) 
solution and stored in a refrigerator until further use. This 
formulation was designated as MNP-CUR. The CUR loading 
estimation was determined using an ultraviolet-visible 
(UV-Vis) spectrophotometer (BioMate™ 3; Thermo Fisher 
Scientific, Pittsburgh, PA) at 450 nm, following a previously 
reported procedure.18,22
Characterization
A transmission electron microscope (TEM) (1210; JEOL 
Ltd, Tokyo, Japan) was employed to determine the size and 
morphology of the MNP-CUR nanoparticles. For this study, a 
sample was prepared by placing the nanoparticle suspension 
(50 µL of 1 mg/mL) on a 200 mesh formvar-coated copper 
TEM grid (grid size: 97 µm; Ted Pella Inc, Redding, CA). 
The excess was removed using a piece of fine filter paper 
and the grid was allowed to air dry prior to imaging under 
the microscope operating at 80 kV .
The particle size, distribution, and zeta potential in 
aqueous medium of the MNP-CUR formulation (50 µL 
of 500 µg/mL dispersed in 3 mL of distilled water and 
ultrasonicated for 30 minutes) were determined by employing 
a Delsa™ Nano C particle size analyzer (Beckman Coulter, 
Brea, CA). Particle size and distribution was measured for 
3 minutes, and the zeta potential was measured for 90 runs 
(9 minutes).
Fourier transform infrared (FTIR) spectral study was 
conducted for dry MNP and MNP-CUR (obtained by 
lyophilization using a Labconco Freeze Dry System, −48°C, 
133 × 10−3 mbar; Labconco Corporation, Kansas City, MO). 
The FTIR of nanoparticles was recorded at a scanning 
speed of 4 cm−1 between 4000–750 cm−1 (32 scans) on 
an IlluminatIR™ FT-IR microscope (Smiths Detection, 
Danbury, CT).
In vitro CUR release
CUR release from the MNP-CUR formulation was carried 
out in a PBS (154 mM, pH 7.4) solution containing 0.1% 
weight/volume Tween-80® (Sigma-Aldrich) at 37°C at 100 
rpm in an orbital shaker (Max Q™ 4000 series; Thermo 
Fisher). Briefly, 2 mg of MNP-CUR was suspended in 3 mL 
PBS solution in a 5 mL tube. At predetermined intervals, 
the tube was centrifuged at 10,000 rpm for 30 minutes and 
supernatant was stored at 4°C in the dark. Then fresh buffer 
solution was replaced in the tube to redisperse the pellet. 
The collected supernatants were measured for absorbance at 
450 nm using a UV-Vis spectrometer as described earlier.22 
An identical standard of CUR (0–10 µg/mL) was prepared 
and absorbance was measured at 450 nm using the UV-Vis 
spectrometer to estimate the amount of CUR released from 
MNP-CUR.
Nanoparticles cellular uptake
A stable nanoformulation is determined by its cellular 
uptake which is one of the important parameters for drug 
delivery applications. To verify this phenomenon, the 
uptake capacity of MNP-CUR formulation was evaluated 
in MDA-MB-231 cancer cells. Cells (5 × 105) were seeded 
in six-well plates in 2 mL medium. After 24 hours, media 
was replaced with medium containing 0–30 µM MNP-CUR. 
After 6 hours incubation time, cells were washed twice with 
PBS and stained with Prussian blue to detect iron presence 
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in the cancer cells.34 Cell images were captured using an 
EVOS® phase contrast microscope (Advanced Microscopy 
Group, Bothell, WA).
To further validate this cellular uptake (internalization) 
behavior of MNP-CUR, TEM was employed. This study 
provides clear evidence of the presence of nanoparticle 
internalization at higher magnification. For this experiment, 
1 × 107 cells per 150 mm plate were incubated with 20 µM 
of MNP-CUR in 20 mL media for 6 hours. These cells 
were centrifuged to remove unbound or uninternalized 
nanoparticles, fixed with standard ice cold formaldehyde 
(4%)-glutaraldehyde (1%) fixative solution followed by 
osmium tetroxide fixative solution, and imaged under TEM, 
following a previously published method.22
Protein adsorption
The protein adsorption on the surface of MNP-CUR was 
evaluated following a developed protocol.35 For this ex 
vivo study, 20 µL of human or mouse serum was added to 
MNP-CUR formulation (1 mg/mL) and stirred for 2 hours at 
25°C. The serum-bound MNP-CUR formulation pellet was 
collected after centrifugation at 10,000 rpm for 30 minutes. 
The MNP-CUR pellet was redispersed in 3 mL water and 
measured for particle size using a particle size analyzer and 
TEM as described above.
In vitro cytotoxicity
Methyl tetrazolium salt (MTS) assay
To assess in vitro cytotoxicity of CUR and MNP-CUR, 
a standard MTS (3-[4,5-dimethyl-2-yl]-5-[3-carboxy-
methoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium) cell 
proliferation assay (CellTiter 96® AQueous; Promega 
  Corporation, Madison, WI) was employed. For this assay, 
MDA-MB-231 cells (5000 cells/well in 100 µL media) were 
seeded in 96-well plates and allowed to attach overnight. Cells 
were then incubated with desired concentrations (5–40 µM) 
of CUR/MNP-CUR for 2 days. Equivalent amounts of 
dimethyl sulfoxide (DMSO) or MNP in PBS served as 
controls for this experiment. After 2 days, the media was 
replaced with fresh media (100 µL) and MTS reagent (25 µL) 
in each well. After 2 hours, the color intensity resulting from 
the formation of soluble formazan product was measured 
at 492 nm using a microplate reader (BioMate 3 UV-Vis 
spectrophotometer). This absorption reading is directly 
proportional to the number of live cells in the culture. The 
percentage of cell growth was presented as the percentage 
of the absorption of treated cells to the absorption of non-
treated cells. Data presented are from six replicates.
Colony formation assay
Colony formation assay was employed to determine the long-
term anticancer potential of the CUR/MNP-CUR formulation. 
In brief, MDA-MB-231 cancer cells were seeded at a density 
of 1000 per well in six-well plates in 2 mL medium and 
allowed 2–3 days to begin formation of colonies. Then, 
cells were treated with different concentrations (4–8 µM) 
of CUR or MNP-CUR over a period of 10 days. The plates 
were washed three times with PBS, fixed in chilled methanol, 
stained with hematoxylin (Thermo Fisher), washed with tap 
water and air dried. The density of colonies was counted 
according to a previous method using a Multimage™ light 
cabinet (Alpha Innotech Corporation, San Leandro, CA) 
with the help of AlphaEaseFC™ (Alpha ImagerHP AIC) 
software.18,21 The percent density of colonies was calculated 
using the density of colonies formed in treatment divided by 
the density of colonies formed in DMSO or MNP in PBS. 
Data presented are from triplicate studies.
Mitochondrial membrane potential
The loss of mitochondrial membrane potential is a direct 
indication of the apoptosis. This can be detected by a cat-
ionic fluorescent red-orange dye, tetramethyl rhodamine 
ethyl ester (TMRE; Invitrogen). For this experiment, MDA-
MB-231 cells (1 × 106) were seeded in a 100-mm Petri dish 
and allowed to attach overnight. These cells were exposed to 
medium containing 5 µM and 10 µM CUR or MNP-CUR and 
incubated for 24 hours at 37°C. Cells treated with DMSO and 
MNPs without CUR in medium served as controls. The cells 
were then washed twice with PBS and incubated with 100 nM 
TMRE for 20 minutes at 37°C in medium without phenol 
red. After completion of the incubation period, cells were 
washed twice with PBS, trypsinized, and collected in 1 mL 
medium containing hydroxyethyl piperazineethanesulfonic 
acid without phenol red. Cell images were captured using an 
Olympus® 1X71 microscope equipped with a DP71 camera 
(Olympus Corporation, Tokyo, Japan). Quantitative TMRE 
fluorescence stain in mitochondria was detected by injecting 
25 µL cell suspension into an Accuri® C6 flow cytometer (BD 
Accuri Cytometers, Ann Arbor, MI) to determine the mean 
fluorescence levels in the FL2 channel. The experiment was 
conducted in triplicate.
Reactive oxygen species (ROS)
For this experiment, MDA-MB-231 cells (1 × 106) were 
plated in a 100-mm Petri dish and allowed to attach 
overnight. Then the medium was replaced with medium 
containing 5 µM and 10 µM CUR or MNP-CUR and 
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incubated for 24 hours at 37°C. Cells treated with DMSO 
and nanoparticles without CUR in medium served as 
controls. After that, these cells were washed twice with 
PBS and treated with 5 µM MitoSOX™ Red mitochondrial 
superoxide indicator (Invitrogen) for 20 minutes at 37°C in 
medium without phenol red. MitoSOX is rapidly oxidized 
by superoxide and this complex is highly fluorescent upon 
binding to nucleic acid. Cell images were taken using an 
Olympus 1X71 microscope equipped with a DP71 camera. 
The production of ROS was detected by injecting 25 µL cell 
suspension into an Accuri C6 flow cytometer to determine the 
mean fluorescence levels in the FL2 channel. The experiment 
was conducted in triplicate.
In vitro MRI
MNP and MNP-CUR formulations were diluted in 3% agar 
solution and final concentration of formulations in agar 
solution was kept between 10–40 µg iron/mL. MRI experi-
ments were performed at 25°C with a 9.4 T (400 MHz H1), 
89 mm vertical bore MRI scanner equipped with triple axis 
gradients (100 G/cm) and a 4-cm Millipede transmit/receive 
radiofrequency coil (Agilent Technologies, Santa Clara, CA). 
Tubes containing formulations in agar solution were placed 
into the MRI scanner and a number of spin-echo sequences 
were run to determine both T1 and T2 relaxation times. T2 
relaxation time was measured using a spin-echo nuclear 
magnetic resonance spectra analysis sequence with 32 echo 
times arrayed exponentially from 5–300 milliseconds and 
the repetition time of 8000 milliseconds. Similarly, the T1 
relaxation time was measured by varying repetition times 
between 100–6400 milliseconds while keeping the echo time 
constant at 8 milliseconds. Relaxation rates R1 (1/T1) and 
R2 (1/T2) were calculated by monoexponential curve fitting 
of the signal intensity versus time (echo time or repetition 
time) using Origin® 6.1 software (OriginLab Corporation, 
Northampton, MA). Equations (1) and (2) were used for 
curve fitting of relaxation rates R1 and R2, respectively:36
 R 1 = A × [1 – exp (−R1 × TR)]  (1)
 R 2 = A + C × [exp (−R2 × TE)]  (2)
T1 relaxivity (r1) and T2 relaxivity (r2) were calculated from 
the slope of plot of R1 versus iron concentration and R2 versus 
iron concentration in agar gels, respectively. TR represents 
repetition time and TE represents echo time.
Magnetic targeting
Magnet-mediated delivery, ie, magnetic drug targeting, can 
increase cellular uptake of nanoparticles in cancer cells and 
improve localized delivery of the encapsulated drug. For 
magnetic drug targeting, MDA-MB-231 cells (2 × 105) were 
seeded in six-well plates and allowed to attach overnight. The 
following day, cells were treated for 3 hours with 2.5, 5, and 
7.5 µM of CUR or MNP-CUR or MNP-CUR in the presence 
of a neodymium external magnet (1″ Dia x 3/32″ thick Rare 
Earth Magnet Disc; Amazing Magnets, Irvine, CA). Cells 
treated with DMSO, MNP, and MNP with magnet served 
as controls. Cells were then washed with PBS three times 
to remove unbound and uninternalized CUR/MNP-CUR. 
Medium without phenol red was added to the dishes to image 
using a fluorescence microscope (Olympus 1 × 71). After 
imaging, cells were collected in 1 mL medium by harvest-
ing with trypsin and analyzed for semiqualitative cellular 
uptake of CUR and MNP-CUR using flow cytometry.19,21,22 
The inherent fluorescence property of CUR was utilized to 
evaluate cellular uptake.
Statistical analysis
The data was processed using Microsoft Excel 2007 software 
and presented as mean ± standard error of the mean. Statistical 
analyses were performed using an unpaired, two-tailed 
Student’s t-test. The level of significance was set at *P , 0.05. 
All graphs were plotted using Origin 6.1 software.
Results and discussion
Nanotheranostics is a multidisciplinary approach in medicine   
composed of therapy and imaging/diagnostic applications.25,26 
To achieve such multiple functions in a single nanoformulation, 
a multidisciplinary collaborative expertise involving 
chemistry, drug delivery, materials science, and biological 
sciences is required. MNPs are considered one of the 
important materials for theranostic applications due to 
their inherent low particle size, high magnetization values, 
biocompatibility, and ability to load biomolecules or drug 
molecules.24 Therefore, development of monodispersed MNPs 
is essential for biomedical applications. Numerous methods 
have been developed following various coating approaches 
to fabricate magnetic nanoformulations with well-defined 
particle size and shape.37,38 These approaches still need to 
overcome destabilization mechanisms such as Ostwald 
ripening, flocculation, phase inversion, and creaming. To 
improve the features of these magnetic nanoformulations, 
a simple precipitation approach was designed where an 
iron oxide nanoparticle core was prepared in the presence 
of CD and subsequently coated with pluronic polymer 
F68 (poly[ethylene-co-propylene glycol]) (Figure A1, 
Appendix). CD selection in this formulation was based 
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upon its combination of hydrophilic units (−OH) which can 
bind to the iron oxide nanoparticle surface and is capable of 
including anticancer drug(s) via the hydrophobic cavity.21,39 
Additional coating with F68 polymer results in a hydrophobic 
(polypropylene, polypropylene oxide) chain which can 
bind to the hydrophobic cavities of CD and the hydrophilic 
(polyethylene glycol, polyethylene oxide) chain provides 
additional hydrophilicity and stability to particles.22,40,41 
CD and F68 polymer coating resulted in reduction of the 
nanoparticle aggregation phenomenon (Figure A1, Appendix). 
Similar patterns of decreased nanoparticle aggregation were 
observed in dynamic light scattering particle size analysis, ie, 
the aggregative particle size of nanoparticles decreased from 
208 nm to 116 nm (Figure A1, Appendix). However, the size 
of the individual nanoparticle grain remained unchanged. 
The diameter of particles observed in TEM was smaller 
than that detected by the dynamic light scattering method 
because TEM observations were of the nanoparticles in dry 
form while dynamic light scattering observations were of the 
nanoparticles in aqueous suspensions.
Figure 1A illustrates the hypothetical single nanoparticle 
layer structure of MNP-CUR formulation where CUR drug 
molecules are positioned in CD layer(s). The TEM image of 
MNP-CUR demonstrates individual nanoparticle grains had 
an average size of about 9 nm (Figure 1B). Dynamic light scat-
tering data of MNP-CUR reveals the particles aggregative size 
averaged 123 nm (Figure 1C) with unimodal and narrow size 
distribution, and contained a polydispersity index of 0.172. 
This indicates minimal change in particle aggregative size 
after CUR loading in MNP formulation (ie, MNP formulation 
aggregative particle size was 116 nm; Figure A1, Appendix). 
In addition, overall aggregative particles can be seen in low 
magnification TEM images which detect average aggregative 
size of nanoparticles .120 nm (Figure A1B, Appendix). The 
average hydrodynamic particles size of MNP-CUR (123 nm) 
was considerably smaller than various multilayer iron oxide 
formulations prepared by coprecipitation approaches.31,40 The 
physical stability of a nanoparticle solution can be predicted 
by the zeta potential of the formulation. The zeta potential of 
the MNP-CUR formulation was −0.66 mV which allows good 
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Figure 1 Physicochemical characterization of curcumin-loaded magnetic nanoparticle formulation. (A) hypothetical schematic representation of curcumin-loaded single 
magnetic nanoparticle formulation. (B) Transmission electron microscopic image of curcumin-loaded magnetic nanoparticle formulation. Data show an individual particle 
grain size of ∼9 nm. (C) Dynamic light scattering measurement of curcumin-loaded magnetic nanoparticle formulation. Data demonstrates the average nanoparticle aggregative 
size is 123 nm. Data represents the average of three replicates. (D) Fourier transform infrared spectra of magnetic nanoparticle formulation, curcumin, and curcumin-loaded 
magnetic nanoparticle formulation. Data was obtained for dry powder samples. (E) In vitro curcumin release from curcumin-loaded magnetic nanoparticle formulation. Inset 
tubes depict curcumin release at different time points (0.4–28 days). Data represents the mean ± standard error of the mean for three repeats. 
Abbreviations: CUR, curcumin; MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; NP, nanoparticle.
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stability during storage. The slightly negative zeta potential 
was attributed to the F68 polymer. Because the zeta potential 
for nanoparticles in solution is a slightly negative value, the 
nanoparticles may likely repel each other resulting in less 
aggregation. A similar observation was found in the case of 
oleic acid-F127 pluronic polymer-stabilized MNPs.41
The chemical difference between MNP and MNP-CUR 
formulations was evaluated by FTIR analysis (Figure 1D). 
FTIR of MNPs (black color spectrum) clearly showed a 
broad peak between 3600–3050 cm−1 due to the presence of 
hydroxyl groups of iron oxide core/CD/F68 polymer, and an 
intense band at 1010 cm−1 due to glycosidic C–O–C vibration 
of CD and F68 polymer.21,32,40,42 FTIR analysis of CUR (red 
color) revealed peaks at: 1610 cm−1 and 1500 cm−1 due to 
C=C and C=O of benzene ring, respectively, 1438 cm−1 due 
to olefinic C–H bending vibration, 1280 cm−1 due to aromatic 
C–O stretching vibrations, and 985 cm−1 due to C–O–C 
stretching vibrations. FTIR spectrum of the MNP-CUR 
formulation demonstrated peaks related to CUR, in addition 
to MNP related peaks, that are consistent with the authors’ 
previous reports (on poly[lactic-co-glycolic acid]-CUR 
nanoparticles and CD-CUR nanoassemblies) and published 
literature.19,21,43,44
The loading efficiency of therapeutic drugs in nano-
particles directly influences the therapeutic outcome of the 
system. CUR is a known anticancer and chemopreventive 
molecule.8 However, its use is limited due to its low bioavail-
ability and poor pharmacokinetics. Therefore, a MNP-CUR 
nanosystem was developed to increase the bioavailability, 
pharmacokinetics and subsequently improve the therapeutic 
efficacy of CUR. The dual layer MNP formulation permitted 
loading of 94.2 µg of CUR per mg of nanoparticles. This 
level of drug loading was likely achieved because the 
presence of a CD layer shell at the interface of the MNP 
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Figure 2 Curcumin-loaded magnetic nanoparticle formulation improves curcumin cellular uptake. (A) Phase contrast images of MDA-MB-231 cancer cells treated with 
curcumin-loaded magnetic nanoparticle formulation (0–30 µM). The intensity of blue stain produced by Prussian blue from the iron of curcumin-loaded magnetic nanoparticle 
formulation helps improve visualization of internalized nanoparticles of curcumin-loaded magnetic nanoparticle formulation. White arrows highlight less internalization of 
nanoparticles and red arrows indicate greater accumulation of nanoparticles. (B) Transmission electron microscopic images of free MDA-MB-231 cells and MDA-MB-231 cells 
incubated with curcumin-loaded magnetic nanoparticle formulation (20 µM) for 6 hours. Black arrows indicate the accumulation and internalized nanoparticles (curcumin-
loaded magnetic nanoparticle formulation) and red arrows represent the vacuole and lysosomal activity which induces apoptosis. 
Abbreviations: MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; N, nucleus.
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core and F68 polymer chains may prevent the diffusion 
of CUR.21,45,46 Figure 1E demonstrates the release profile 
of CUR from MNP-CUR under in vitro conditions. A slow 
and sustained release of CUR from MNP-CUR was noticed 
throughout the study (for 28 days). About 47% CUR release 
occurred in the first 5 days. Therefore, this data clearly sup-
ports the proposition that CUR release is highly controlled 
by the CD layer. Since CUR is a hydrophobic molecule, it 
therefore remains in the CD layers (hydrophobic cavity) 
rather than transfer to the aqueous phase. Additionally, 
the F68 polymer chains (polypropylene oxide units) may 
also restrict the release of CUR into aqueous medium. 
Therefore, the MNP-CUR formulation exhibited controlled 
and sustained release of CUR which may ensure its efficient 
anticancer activity and prevent the cancer from developing 
drug resistance.47
Cellular uptake
Improved intracellular accumulation or uptake of drug 
nanoparticles in cancer cells is an indication for a higher 
therapeutic index.16 Therefore, this step of the present 
study investigated the qualitative uptake of MNP-CUR 
by MDA-MB-231 cells. The uptake of MNP-CUR was 
visualized by Prussian blue staining. A clear accumulation 
pattern of MNP-CUR was observed in MDA-MB-231 cancer 
cells: accumulation increases as the MNP-CUR concentration 
increases (faint blue [white arrows] to dark blue [red arrows]; 
Figure 2A). The internalized particles localized in almost 
every cell and throughout the cell components. This type of 
formulation showed very minimal uptake by macrophages, 
which supports increased circulation time for a more 
effective therapy.22,41 It is also logically possible to improve 
the internalization capacity of this type of nanoparticle by 
a ligand/antibody/penetrating peptide.48 Their high affinity 
allows preferential internalization through receptor mediated 
endocytosis; in this manner nanoparticle(s) efficiently target 
cancer cells.
To further prove MNP-CUR intracellular localization in 
MDA-MB-231 cancer cells, a TEM study was performed. 
In this study, after 6 hours treatment with MNP-CUR, 
MDA-MB-231 cancer cells were cross-sectioned (90 nm) 
using an ultramicrotome and viewed under TEM according 
to a previously reported method.19 Interestingly, most of the 
MNP-CURs were located as clusters in the cell structure, 
a phenomenon which was completely absent in control 
cells (Figure 2B). A magnified view of MNP-CUR uptake 
is also presented in Figure A2, Appendix. Therefore, it is 
clear that MNP-CURs underwent endocytosis but were not 
physically bound to the cancer cell surface. The authors 
propose that the entrapped MNP-CUR will demonstrate its 
anticancer properties by delivering CUR more efficiently to 
cancer cells. Control cancer cells were not affected at ultra-
structural level and did not show any changes in cellular 
integrity. However, it is very clear that cancer cells treated 
with MNP-CUR exhibit ultra-structural changes, including 
shrinkage in nucleus, vesicle, and vacuole formation which 
represent onset of apoptosis.19,49
Protein binding
The final aim is to develop MNP-CUR for preclinical 
and human applications. Serum protein quickly binds to 
the surface of nanoparticles and changes their fate before 
reaching the intended target(s). This binding affinity of 
protein may depend on particle size and surface properties 
of the nanoparticles.49 Properties (in this case particle size) 
of stable drug nanoformulations may not be affected by the 
protein absorption during circulation in blood. To check 
this phenomenon, MNP-CUR formulation was incubated 
with human and mouse serum, and their particle size was 
measured using TEM and dynamic light scattering. Figure 3A 
demonstrates no significant change in the aggregation of 
MNP-CUR formulation before and after incubation with 
human serum and mouse serum. However, there was a 
slight change in the surface morphology when incubated 
with mouse or human serum. Similarly, a slight increase 
in particle size was observed after incubation with mouse 
or human serum (MNP-CUR-mouse serum, 136 nm; 
MNP-CUR-human serum, 144 nm) compared to control 
nanoparticles (MNP-CUR, 123 nm) (Figure 3B). The increase 
in particle size may be attributed to the adsorbed layers of 
serum proteins.50
Anticancer potential
It is imperative to assess the cytotoxicity of developed 
MNP-CUR for its potential anticancer application(s). 
The evaluation of cytotoxic activity was performed by 
direct observation of cell morphology as well as MTS 
assay. Evaluation by two different methods was conducted 
because some recent reports suggest that cytotoxicity assay 
reagents may interfere with nanoformulations.51,52 Cell 
image/morphology evaluation (Figure 4A) and MTS assays 
(Figure 4B) provide a direct qualitative and quantitative 
assessment of the anticancer potential of CUR/MNP-CUR 
formulations. When cells were treated with CUR, the viability 
of the cancer cells decreased sharply in a concentration 
(10–30 µM)-dependent manner (Figure 4A). A similar pattern 
was observed with MNP-CUR at all tested concentrations 
(Figure 4A). Interestingly, cell morphology was drastically 
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Figure 3 Curcumin-loaded magnetic nanoparticle formulation particle size is not influenced by human and mouse serum protein adsorption. (A) Curcumin-loaded magnetic 
nanoparticle formulation particles morphology viewed under transmission electron microscope before and after incubation with human and mouse serum. (B) Particle size 
of curcumin-loaded magnetic nanoparticle formulation before and after incubation with human and mouse serum. 
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Figure 4 Curcumin-loaded magnetic nanoparticle formulation treatment increases the anticancer potential in MDA-MB-231 cells. (A and B) Cells were treated with different 
concentrations (5–40 µM) of curcumin or curcumin-loaded magnetic nanoparticle formulation; medium was changed on day two. (A) Representative phase contrast images of MDA-
MB-231 cells treated with vehicle (dimethyl sulfoxide or magnetic nanoparticles) and 10–30 µM curcumin or 10–30 µM curcumin-loaded magnetic nanoparticle formulation. Images 
obtained at 2000×. (B) Cell viability was measured using methyl tetrazolium salt assay using an ultraviolet-visible spectrophotometer at 492 nm. Data is mean ± standard error of the 
mean (n = 6). Dimethyl sulfoxide and magnetic nanoparticle formulation controls did not show any effect at these concentrations. (C and D) Cells were treated with either 4–8 µM 
of curcumin or curcumin-loaded magnetic nanoparticle formulation for 10 days. (C) Representative images of colonies stained with hematoxylin. (D) Colony density was counted 
and expressed as a percent of the control. Data represent mean of triplicate for each treatment (mean ± standard error of the mean). *P , 0.05 for significance difference. 
Abbreviations: CUR, curcumin; DMSO, dimethyl sulfoxide; MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; NPs, nanoparticles.
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changed and the number of cancer cells was greatly reduced 
even at 10 µM MNP-CUR. A very limited number of cancer 
cells were observed after treatment with 20 µM and 30 µM 
of CUR/MNP-CUR. CUR/MNP-CUR-treated cells were 
clearly distinguished with plasma membrane smoothing, 
blebbing, and loss of spindle morphology, and were almost 
detached, which is an apoptosis feature. Treatments with 
various CUR and CUR nanoformulations also have reported 
this apoptosis feature in the number of cancer cells.16,23 The 
MTS assay data demonstrated a concentration-dependent 
antiproliferative effect (5–40 µM) by CUR and MNP-CUR 
formulations (Figure 4B) as observed in the study of cellular 
images. The half maximal inhibitory concentration (50% cell 
growth inhibitory concentration) was calculated as 17.2 µM 
with CUR and 12.4 µM with MNP-CUR treatment. From 
this data, it can be concluded that although CUR release 
from MNP-CUR formulation was only 40%, it is as equally 
potent as free CUR in suppressing cell growth. Therefore, 
the MNP-CUR formulation can be employed as an efficient 
cancer therapeutic agent.
To further prove that the MNP-CUR formulation holds 
improved anticancer therapeutic potential, a propidium 
iodide stain experiment was performed. Propidium iodide 
specifically binds to double-stranded DNA through the 
plasma membrane of nonviable cells which can be detected 
in flow cytometry in the FL2 channel. MNP-CUR-treated 
cells indicate a significant propidium iodide stain over CUR-
treated cells, suggesting a higher number of dead cells exist 
after MNP-CUR treatment (Figure A3, Appendix). This data 
supports the findings of MTS assay.
The authors’ hypothesis is that since CUR releases 
slowly from MNP-CUR, this formulation may exhibit a 
superior anticancer activity in long term experiments such 
as colony formation assays. For example, magnetoplasmonic 
assembly of the polyethylene glycol-CUR formulation 
demonstrates better anticancer properties after 42–52 hours 
treatment compared to magnetoplasmonic assembly-CUR/
CUR treatment and the efficacy depends on the drug release 
pattern.49 This supports the belief that CUR nanoformulations 
require time to show superior effects. Therefore, the efficacy 
of MNP-CUR on MDA-MB-231 cancer cells was studied. 
A significant decrease was observed in the formation of 
colonies after MNP-CUR treatment compared to CUR 
(Figure 4C). CUR treatment gradually declined formation 
of colony density, ie, 4–8 µM concentration was responsible 
for reducing colony density from ∼100% to 38% (Figure 4D) 
whereas 4 µM MNP-CUR treatment successfully restricted 
colony density to merely 16% (Figure 4D). This result clearly 
indicates that the increased cytotoxicity (reduced colony 
  density) was primarily associated with active CUR release 
from MNP-CUR over time. A similar improved anticancer 
effect in a number of cancer cell lines was observed in 
previous studies using various CUR formulations.18–20 
These studies support this enhanced anticancer potential 
by documenting an increase in apoptosis as demonstrated 
through enhanced cleaved poly(adenosine diphosphate 
ribose) polymerase protein with MNP or other CUR 
nanoformulations.18–20
Mitochondrial membrane potential
The loss of mitochondrial membrane or mitochondrial 
dysfunction is a key indicator of intrinsic apoptosis.42 The 
specificity of mitochondrial stain after 24 hours treatment 
with CUR and MNP-CUR formulations was detected using 
cationic dye TMRE by fluorescence microscopy and flow 
cytometry. TMRE accumulates in the mitochondria when 
a membrane has intact potential. TMRE positive cells are 
an indication of viable cells with high membrane potential. 
Decrease in TMRE stain indicates a loss of mitochondrial 
membrane potential. Microscopy analysis illustrated that 
upon treatment with 5 µM CUR, the cells had a very similar 
amount of stain as control cells; however, after treatment with 
10 µM CUR, the cells showed a significant decrease in stain 
intensity (Figure 5A). In the case of MNP-CUR, both 5 µM 
and 10 µM treatments showed decreased stain, indicating 
effective mitochondrial membrane damage and thus increased 
anticancer potential (Figure 5A). Similar results were observed 
with flow cytometry analysis. A significant decrease in TMRE 
stain was noticed with MNP-CUR treatment compared to 
CUR (Figure 5B). This may be due to higher cellular uptake 
of MNP-CUR, inducing greater loss in membrane potential.
ROS production
Many anticancer drug treatments lead to the generation of 
ROS which is involved in stimulating inflammation, apopto-
sis, and DNA damage which can affect the signaling pathways 
involved in external or internal cell damage.53,54 Although 
CUR is a potent antioxidant with ROS scavenger charac-
teristics, it also induces ROS production in human tumor 
cells.55 A MitoSOX stain was used to identify such intracel-
lular mitochondrial ROS generation from the CUR-treated 
and MNP-CUR-treated cells. ROS production in the CUR-
treated cells was not significantly different from control cells. 
However, the production of ROS was significantly increased 
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in MNP-CUR-treated cells (Figure 6A and B). These results 
further demonstrate that MNP-CUR can efficiently internalize 
and deliver CUR in its active form and is responsible for ROS 
production, while free CUR barely influences the production 
of ROS at the tested concentrations. The obtained results 
corroborate similar findings reported by Mulik et al56 that 
CUR nanoparticles potentiate apoptosis in MDA-MB-231 
cancer cells via generation of ROS.   Similarly, pretreatment 
and cotreatment of CUR nanoparticles with other anticancer 
drugs also leads to an increase in ROS production.57,58
MRI
MNPs exhibit specific inherent magnetic properties that are 
highly important in MRI for increasing the detection limits 
in tissue lesions within the body.24,25,38 In addition, surface-
modified MNPs avoid recognition by the reticuloendothelial 
system and therefore may efficiently target tumors, making 
them a better contrast imaging agent. In this study, the suit-
ability of MNPs and the MNP-CUR formulation as contrast 
imaging agents for MRI was investigated.26,38 Figure 7A 
illustrates an increase of nanoparticle concentration resulting 
in a reduction in T2-weighted signals. Calculated transverse 
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Figure 5 Curcumin-loaded magnetic nanoparticle increases loss of mitochondrial membrane potential. MDA-MB-231 cells (1 × 106) were treated with curcumin and 
curcumin-loaded magnetic nanoparticles (0–10 µM) for 24 hours and the loss of mitochondrial membrane potential was determined using tetramethyl rhodamine ethyl 
ester dye. (A) Representative tetramethyl rhodamine ethyl ester stain in MDA-MB-231 cells after treatment with curcumin and curcumin-loaded magnetic nanoparticle 
formulation. Less intense stain indicates loss of mitochondrial membrane potential. (B) Quantitative estimation of tetramethyl rhodamine ethyl ester stain was analyzed by 
flow cytometry. For this analysis, 10,000 cells were injected into an Accuri® C6 Flow Cytometer (BD Accuri Cytometers, Ann Arbor, MI) and fluorescence levels were 
measured in the FL2 channel. Data represent the mean of three repeats for each treatment (mean ± standard error of the mean). *P , 0.05 for significance difference.
Abbreviations: CUR, curcumin; DMSO, dimethyl sulfoxide; MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; 
RFU, relative fluorescence units.
relaxation times from images (Figure 7A) relative to the con-
trol gel decreased with an increase in nanoparticle concentra-
tion (Figure 7B). Specifically, as the concentration increased 
from 10 µg iron/mL to 40 µg iron/mL, T2 relaxation times 
decreased from 22.4 milliseconds to 5.8 milliseconds. By 
plotting the transverse relaxation rate R2 (1/T2) as a function 
of the concentration of iron in each sample, R2 increased lin-
early with the concentration of iron (Figure 7C). From these 
data, T2 relaxivity (r2) was calculated as 7.040 s−1 µg−1 mL for 
MNP-CUR. The relaxivity was slightly diminished when the 
particles were in the presence of cancer cells (4.38 s−1 µg−1 mL) 
but enhanced values were observed in combination with CUR-
nanoparticles. The relaxivity order detected was 7.040 s−1 µg−1 
mL (MNP-CUR) . 4.38 s−1 µg−1 mL (MNP-CUR in cancer 
cells) . 3.40 s−1 µg−1 mL (MNP) . 2.38 s−1 µg−1 mL (MNP in 
cancer cells). A similar pattern was also observed in T1 relaxiv-
ity (r1): 33.21 s−1 µg−1 mL (MNP-CUR) . 18.663 s−1 µg−1 mL 
(MNP-CUR in cells) . 11.303 s−1 µg−1 mL (MNP) . 6.389 s−1 
µg−1 mL (MNP in cancer cells). The higher relaxivity values 
of MNP-CUR are attributed to CUR and the nanoparticles 
induce greater inhomogeneity in the magnetic field than MNP. 
Similar improved enhanced contrast properties were observed 
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Figure 7 In vitro magnetic resonance image characteristics of magnetic nanoformulations. (A) Signal intensity T2-weighted magnetic resonance images of magnetic nanoparticle 
formulation, magnetic nanoparticle formulation in MDA-MB-231 cancer cells, curcumin-loaded magnetic nanoparticle formulation, and curcumin-loaded magnetic nanoparticle 
formulation in MDA-MB-231 cancer cells in 3% phantom agar gel (10–40 µg/mL) scanned under a 9.4 T vertical bore magnetic resonance image scanner (Agilent Technologies, 
Santa Clara, CA) at 25°C. (B) T2 relaxation curves of magnetic nanoformulations in phantom agar gel. (C) T2 relaxation rate R2 (1/T2) plotted as a function of the iron 
concentration for magnetic nanoformulations. 
Abbreviations: MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; TE, echo time.
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Figure 8 Curcumin-loaded magnetic nanoparticle formulation magnetic targeting improves curcumin uptake by MDA-MB-231 cells. (A) Schematic representation of 
experimental design for magnetic targeting. Cells (2 × 105) were seeded in six-well plates and treated for 3 hours with 2.5, 5, and 7.5 µM of (1) curcumin, (2) curcumin-loaded 
magnetic nanoparticle formulation, or (3) curcumin-loaded magnetic nanoparticle formulation in the presence of a neodymium external magnet. (B) Curcumin uptake by 
cancer cells was visualized using a fluorescence microscope (1X71; Olympus Corporation, Tokyo, Japan). (C) Internalized fluorescence levels were analyzed using an Accuri® 
C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI) in the FL1 channel. Data represent the mean of three repeats for each treatment (mean ± standard error of the 
mean) and expressed in fold change compared to respective controls. *P , 0.05 for significance difference.
Abbreviations: CUR, curcumin; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation.
with drug-loaded formulations due to the color(s) contributed 
by the drug(s), such as yellow (CUR) or red (doxorubicin).21,31,39 
Previous reports support that these multilayer-coated MNPs 
may have superior imaging characteristics over conventional 
magnetic nanoformulations.40,41
Magnetic targeting
Ideal magnetic field mediated drug delivery (magnetic 
targeted drug delivery) facilitates drug accumulation in 
cells possibly by passive diffusion, adsorptive transcytosis, 
and receptor mediation.59 This advanced drug targeting 
approach is increasingly utilized due to increased site 
specificity with fewer side effects.26 However, efficiency of 
magnetic field-mediated cellular delivery of drug depends 
on the applied external magnetic field as well as the type 
of MNP carrier.25,38,60,61 To determine the potential utility 
of the nanoformulations for possible magnetic targeting, 
MDA-MB-231 cancer cells treated with MNP-CUR were 
exposed to a neodymium external magnet for 3 hours. 
A detailed schematic representation of the experiment 
design is presented in Figure 8A. The results were evaluated 
comparing CUR/MNP-CUR internalization in the cancer 
cells. CUR (2.5–7.5 µM) exposed cells exhibited a 
very minute amount of CUR. MNP-CUR-treated cells 
demonstrated significant cellular uptake of CUR through 
the influence of magnetic field (Figure 8B). This effect was 
only minimal when there was no magnetic field applied 
(Figure 8B). Overall, qualitative accumulation/cellular uptake 
of CUR assessed by flow cytometry was clearly enhanced 
by magnetic field (Figure 8C) at all the concentrations 
tested. Thus, exposure to external magnets significantly 
increased the cellular uptake of MNPs predominantly into 
malignant cells. This study suggests that application of an 
external magnetic field would enhance additional CUR 
internalization, inducing more cellular apoptosis, thereby 
increasing the possible cytotoxicity of MNP-CUR.
Overall, the data show the feasibility of using an 
innovative nanoparticle system which combines magnetic 
targeting of a therapeutic agent (CUR) with both magnetic 
resonance and fluorescence imaging in a single system 
(Figure 9). This formulation can be extended to other 
clinically used therapeutic drugs and can be developed as 
antibody conjugation features.41 Targeting efficacy of these 
multifunctional nanoparticles specifically to triple-negative 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1773
Curcumin magnetic nanoparticles for theranostic applicationsInternational Journal of Nanomedicine 2012:7
breast cancer cells can be further enhanced clinically through 
conjugation of monoclonal antibodies, such as antitransfer-
rin (Figure A4, Appendix), glucose transporter 1, and folic 
acid.62,63
Conclusion
Development of safe, efficient, and biocompatible drug 
nanoformulations with theranostic properties is essential 
for clinical translation in cancer therapy. A composite 
MNP formulation composed of an iron oxide nanoparticle 
core coated with CD and pluronic polymer (F68) with 
CUR loading capability was developed. This formula-
tion exhibited improved uptake in cancer cells, increased 
loss of mitochondrial membrane potential, and produced 
higher ROS, suggesting it is extremely valuable in anti-
cancer   therapeutics. Additionally, enhanced MRI proper-
ties   (compared to conventional MNPs) demonstrate this 
formulation has good imaging agent characteristics. More 
importantly, magnetic targeting of MNP-CUR facilitated 
an enhanced delivery of CUR to cancer cells. All together, 
these findings indicate that this formulation is appropri-
ate for utilization in engineered delivery systems for 
theranostic applications in efficient image-directed cancer 
therapeutics.
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Figure A1 Composition and particle size evaluation of magnetic nanoparticles. (A) Schematic representation of the synthesis route of a multifunctional magnetic nanoparticle. 
Iron oxide (magnetic) nanoparticles prepared by chemical precipitation reaction in presence of β-cyclodextrin and subsequent F68 polymer coating leads to magnetic 
nanoparticle nanoformulation. (B) Transmission electron microscopic image of pure iron oxide core nanoparticles (no coating with β-cyclodextrin/F68 polymer), iron oxide 
nanoparticles coated with 100 mg of β-cyclodextrin, and iron oxide nanoparticles coated with 100 mg of β-cyclodextrin and 200 mg of F68 polymer. Data show an individual 
particle grain size of ∼9 nm. (C) Dynamic light scattering particle size data of (1) pure iron oxide core nanoparticles, (2) iron oxide nanoparticles coated with β-cyclodextrin, 
and (3) iron oxide nanoparticles coated with β-cyclodextrin and F68 polymer representing aggregative particles size in aqueous media. 
Note: β-cyclodextrin and F68 polymer coating help to reduce particle aggregative phenomenon. 
Abbreviations: CD-IOCNP, iron oxide core nanoparticles coated with CD (100 mg); F68-CD-IOCNP/MNP, iron oxide core nanoparticles coated with CD (100 mg) and F68 
polymer (200 mg); IOCNP, iron oxide core nanoparticles.
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Figure A2 Magnified view of transmission electron microscopic images of MDA-MB-231 cells after treatment with curcumin-loaded magnetic nanoparticles (20 µM) for 
6 hours. Accumulation of curcumin-loaded magnetic nanoparticles occurs throughout the cytoplasm. 
Note: Red arrows represent nanoparticles accumulation.
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Figure A3 Curcumin-loaded magnetic nanoparticle formulation increases MDA-MB-
231 cell death. Cells (2 × 105) were seeded in six-well plates and treated for 24 hours 
with 2.5, 5, and 7.5 µM of curcumin or curcumin-loaded magnetic nanoparticles. The 
cells were collected both live and dead (floating) and incubated at room temperature 
in the dark with 5 µL propidium iodide for 20 minutes in 2 mL medium containing 
hydroxyethyl piperazineethanesulfonic acid without phenol red. After completion of 
the incubation period, propidium iodide stain was quantified for 5000 cells using 
an Accuri® C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI) in the FL2 
channel. The experiment was conducted in triplicate. 
Abbreviations:  CUR,  curcumin;  MNP-CUR,  curcumin-loaded  nanoparticles;   
PI, propidium iodide.
24,000 *
*
*
Transferrin-FITC
MNP-transferrin-FITC
18,000
12,000
6000
0
50
Antibody concentration (µg)
M
e
a
n
 
f
l
u
o
r
e
s
c
e
n
c
e
 
(
R
F
U
)
100 150
Figure A4 Antitransferrin-fluorescein isothiocyanate antibody conjugation promotes 
magnetic nanoparticles targeting MDA-MB-231 cancer cells. Cells (2 × 10 5) were seeded 
in six-well plates and treated for 24 hours with 50, 100, and 150 µg of antitransferrin-
fluorescein  isothiocyanate  antibody  or  magnetic  nanoparticles  conjugated  with 
antitransferrin-fluorescein isothiocyanate antibody. The cells were trypsinized and 
collected  in  1  mL  medium  containing  hydroxyethyl  piperazineethanesulfonic  acid 
without phenol red. Fluorescein isothiocyanate levels were analyzed for 5000 cells 
using an Accuri® C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI) in the 
FL1 channel. The experiment was conducted in triplicate. 
Note:  Antitransferrin-fluorescein  isothiocyanate  conjugation  was  performed 
according to previous protocol.19 In detail, 5 mg of magnetic nanoparticles and 1 mg 
of  eight-arm  N-hydroxysuccinimide–polyethylene  glycol–N-hydroxysuccinimide 
linker (Nanocs Inc, Boston, MA) were dispersed in 1 mL phosphate buffered saline. 
After 1 hour, 500 µg of antitransferrin-fluorescein isothiocyanate was mixed and 
allowed to link onto magnetic nanoparticles overnight. To this mixture, 500 µg of 
bovine serum albumin was added to nullify excess N-hydroxysuccinimide reactivity. 
The conjugation efficiency was found to be 92%. 
Abbreviations:  MNP-transferrin-FITC,  magnetic  nanoparticles  conjugated  with 
antitransferrin-fluorescein isothiocyanate antibody; RFU, relative fluorescence units; 
transferrin-FITC, antitransferrin-fluorescein isothiocyanate antibody.
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